Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting
Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ PlatformREDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE)...
Vaccine
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025
Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of...
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents...
Moderna Named a Top Employer by Science for Tenth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top...
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024
CHATHAM, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage...
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present...
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company...
BuzzRx® Introduces Vaccination Scheduling Functionality
Tool Helps Customers Find and Schedule Vaccine Appointments at CVS Pharmacy FORT LAUDERDALE, Fla., Oct. 22, 2024 /PRNewswire/ -- BuzzRx, a free...
Dotmatics Introduces Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery
The first in a series of Dotmatics Luma Multimodal R&D Solutions Geneious has been seamlessly composed into Luma showcasing cross-therapeutic...
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute...
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Company to conduct a Phase 1 Drug-Drug Interaction StudyPhase 2 filing on track for Q1 2025 SOUTH SAN FRANCISCO, Calif.,...
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
Determined the high dose of OCU410ST to be the maximum tolerated doseNo serious adverse events have been reportedApproved proceeding to...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults...
Bioprocessing Market Size Worth $72.55 Billion, Globally, by 2031 – Exclusive Report by The Insight Partners
The Bioprocessing Market share is expected to reach US$ 72.55 billion by 2031 from US$ 25.35 billion in 2023 to record...
Global Health Exhibition Launches in Riyadh, Witnessing SAR 50 Billion in Investments on its First Day
RIYADH, Saudi Arabia, Oct. 21, 2024 /PRNewswire/ -- The seventh edition of the Global Health Exhibition has kicked off under the...
Global Health Exhibition Opens its Doors Tomorrow to Record-Breaking 100,000+ Attendees to World’s Premier Healthcare Transformation Event
Kingdom of Saudi Arabia opens the Global Health Exhibition (21-23 October 2024) tomorrow, a major international healthcare event with 100,000+...
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live...
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live...